MS-DRG v44.0 · MDC 17: Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
839 — Chemotherapy with Acute Leukemia as Secondary Diagnosis without CC/MCC
- Relative weight
- 1.3782
- Geometric mean LOS
- 3.7 days
- Arithmetic mean LOS
- 4.2 days
- Type
- Medical
About MS-DRG 839
MS-DRG 839, Chemotherapy with Acute Leukemia as Secondary Diagnosis without CC/MCC, is a medical DRG in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms) under MS-DRG version 44.0, which applies to inpatient discharges from October 1, 2026 through September 30, 2027.
Its FY2027 relative weight is 1.3782, so Medicare's base payment for this DRG is about 1.38 times the average inpatient case, before hospital-specific adjustments. The geometric mean length of stay is 3.7 days and the arithmetic mean is 4.2 days.
It belongs to a 3-level severity family: DRG 837 (or with High Dose Chemotherapy Agent with MCC, weight 4.7124), DRG 838 (with CC or High Dose Chemotherapy Agent, weight 2.1585) and DRG 839 (without CC/MCC, weight 1.3782). The highest-severity level carries 3.4 times the weight of the lowest, which is why documenting CC and MCC conditions matters.
36 ICD-10-CM diagnosis codes are part of this DRG's grouping logic; they are listed below.
ICD-10-CM codes that group to DRG 839 (36)
Chapter 2: Neoplasms
- C91.00Acute lymphoblastic leukemia not having achieved remission
- C91.01Acute lymphoblastic leukemia, in remission
- C91.02Acute lymphoblastic leukemia, in relapse
- C92.00Acute myeloblastic leukemia, not having achieved remission
- C92.01Acute myeloblastic leukemia, in remission
- C92.02Acute myeloblastic leukemia, in relapse
- C92.40Acute promyelocytic leukemia, not having achieved remission
- C92.41Acute promyelocytic leukemia, in remission
- C92.42Acute promyelocytic leukemia, in relapse
- C92.50Acute myelomonocytic leukemia, not having achieved remission
- C92.51Acute myelomonocytic leukemia, in remission
- C92.52Acute myelomonocytic leukemia, in relapse
- C92.60Acute myeloid leukemia with 11q23-abnormality not having achieved remission
- C92.61Acute myeloid leukemia with 11q23-abnormality in remission
- C92.62Acute myeloid leukemia with 11q23-abnormality in relapse
- C92.A0Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
- C92.A1Acute myeloid leukemia with multilineage dysplasia, in remission
- C92.A2Acute myeloid leukemia with multilineage dysplasia, in relapse
- C93.00Acute monoblastic/monocytic leukemia, not having achieved remission
- C93.01Acute monoblastic/monocytic leukemia, in remission
- C93.02Acute monoblastic/monocytic leukemia, in relapse
- C94.00Acute erythroid leukemia, not having achieved remission
- C94.01Acute erythroid leukemia, in remission
- C94.02Acute erythroid leukemia, in relapse
- C94.20Acute megakaryoblastic leukemia not having achieved remission
- C94.21Acute megakaryoblastic leukemia, in remission
- C94.22Acute megakaryoblastic leukemia, in relapse
- C94.40Acute panmyelosis with myelofibrosis not having achieved remission
- C94.41Acute panmyelosis with myelofibrosis, in remission
- C94.42Acute panmyelosis with myelofibrosis, in relapse
- C95.00Acute leukemia of unspecified cell type not having achieved remission
- C95.01Acute leukemia of unspecified cell type, in remission
- C95.02Acute leukemia of unspecified cell type, in relapse
Chapter 21: Factors influencing health status and contact with health services
Common questions about DRG 839
What is the relative weight of DRG 839?
- 1.3782 for FY2027 (MS-DRG v44.0), from the IPPS final rule Table 5.
What is the average length of stay for DRG 839?
- The geometric mean length of stay is 3.7 days; the arithmetic mean is 4.2 days.
Is DRG 839 medical or surgical?
- DRG 839 is a medical DRG.